2.73
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
Humacyte rises on Symvess sale to military treatment facility - MSN
Humacyte Inc. Equity Warrant Stock Analysis and ForecastRapid wealth multiplication - jammulinksnews.com
Humacyte shares climb 6% after first Symvess sale to U.S. military hospital - MSN
Is Humacyte Inc. Equity Warrant a good long term investmentUnprecedented profit potential - Autocar Professional
Humacyte stock rises after first Symvess sale to US Military facility - Investing.com India
Humacyte Announces First Symvess™ Sale to Military Treatment Facility - The Manila Times
Humacyte Breaks Into Military Healthcare: FDA-Approved Symvess Now Serving 200,000 Military Personnel - Stock Titan
What drives Humacyte Inc. stock priceFree Consultation - Autocar Professional
What analysts say about Humacyte Inc. stockMassive profits - jammulinksnews.com
Humacyte Inc. Stock Analysis and ForecastFree Advanced Stock Screener Access - jammulinksnews.com
Is Humacyte Inc. a good long term investmentOutstanding risk-reward balance - jammulinksnews.com
What analysts say about Humacyte Inc. Equity Warrant stockConsistently profitable trades - jammulinksnews.com
What drives Humacyte Inc. Equity Warrant stock priceFree Stock Selection - Autocar Professional
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know - MSN
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders - ACCESS Newswire
Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026 - MSN
Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today - MSN
Lobbying Update: $10,000 of HUMACYTE lobbying was just disclosed - Nasdaq
Humacyte jumps as DoD issues ECAT listing approval for Symvess - MSN
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors - MSN
Positive week for Humacyte, Inc. (NASDAQ:HUMA) institutional investors who lost 56% over the past year - simplywall.st
Humacyte's Symvess ECAT Listing: A Strategic Catalyst for Biotech's Comeback - AInvest
Humacyte’s Symvess gains DOD electronic catalog listing approval By Investing.com - Investing.com South Africa
Humacyte's Symvess ECAT Approval: A Strategic Play for Dominance in Vascular Trauma and Beyond - AInvest
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):